$8.55
+5.4%Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Strong working capital position provides significant operational flexibility and financial cushion.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
BVS โข NASDAQ
| Bioventus Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
51.2M | 41.6M | 37M | 30.2M | 43.9M | 86.8M | 64.5M | 42.8M | 5M | 15.8M | |
51.2M | 41.6M | 37M | 30.2M | 43.9M | 86.8M | 64.5M | 42.8M | 5M | 15.8M | |
128.3M | 127.4M | 122.8M | 136.3M | 125M | 88.3M | 85.1M | 73M | 54.5M | 47.1M | |
128.5M | 127.4M | 122.8M | 136.3M | 125M | 88.3M | 85.1M | 73M | 54.5M | 46.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 498K | |
82.2M | 92.5M | 91.3M | 84.8M | 61.7M | 29.1M | 27.3M | 27.4M | 35.2M | 26.7M | |
0.0 | 0.0 | 0.0 | 4.4M | 12.2M | 7.6M | 6.1M | 4.9M | 4.4M | 5.7M | |
11.1M | 14.2M | 16.9M | 16.9M | 20.3M | 0.0 | 0.0 | 224K | 343K | 0.0 | |
272.8M | 275.6M | 268M | 272.6M | 263.1M | 211.8M | 183M | 148.4M | 99.4M | 95.2M | |
NON-CURRENT ASSETS | ||||||||||
27M | 33.5M | 50M | 44.1M | 40.2M | 21.8M | 19.8M | 4.8M | 9.6M | 10.4M | |
7.5M | 7.5M | 7.5M | 7.5M | 147.6M | 49.8M | 49.8M | 49.8M | 58.7M | 50M | |
368.4M | 404.7M | 482.4M | 639.9M | 695.2M | 191.7M | 216.5M | 237M | 319.2M | 274.3M | |
375.9M | 412.2M | 489.8M | 647.3M | 842.8M | 241.5M | 266.3M | 286.8M | 377.8M | 324.3M | |
0.0 | 0.0 | 0.0 | 2.6M | 29.3M | 19.4M | 3.3M | 2.8M | 0.0 | 0.0 | |
5.5M | 4.7M | 0.0 | 0.0 | 481K | 0.0 | 0.0 | 0.0 | 84K | 179K | |
2.3M | 1.9M | 3.1M | 406M | 50M | 0.0 | 0.0 | 0.0 | 393K | 298K | |
410.7M | 452.3M | 542.9M | 1.1B | 962.8M | 282.7M | 289.4M | 294.4M | 387.9M | 335.2M | |
683.6M | 728M | 810.9M | 1.4B | 1.2B | 494.5M | 472.4M | 442.7M | 487.4M | 430.4M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
16.1M | 27.6M | 27.8M | 39.3M | 25.1M | 6.9M | 9M | 8.2M | 8.4M | 6.7M | |
10.9M | 23.7M | 23M | 36.7M | 16.9M | 4.4M | 6.4M | 8.2M | 8.4M | 5.4M | |
5.1M | 3.9M | 4.7M | 2.6M | 8.1M | 2.4M | 2.6M | 0.0 | 0.0 | 1.3M | |
0.0 | 104.4M | 85.6M | 80.6M | 91.3M | 79.9M | 47M | 26.2M | 14.9M | 16M | |
19.2M | 27.3M | 27.8M | 33.1M | 18M | 15M | 10M | 5.3M | 36.5M | 7.2M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 688K | |
0.0 | 3.9M | 4.7M | 2.6M | 8.1M | 2.4M | 2.6M | 2M | 2.7M | 1.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.3M | |
125.1M | 51.1M | 34.2M | 151.1M | 46.5M | 20.9M | 23M | 25.7M | 26.8M | 21.6M | |
160.4M | 210.4M | 175.5M | 304M | 180.9M | 122.6M | 89M | 65.4M | 87.7M | 52.2M | |
NON-CURRENT LIABILITIES | ||||||||||
279M | 308.3M | 367M | 385M | 339.6M | 173.4M | 188M | 189.6M | 157.6M | 162.3M | |
433K | 564K | 1.2M | 2.2M | 133.5M | 3.4M | 3.9M | 4M | 8.8M | 9.3M | |
2.2M | 23.1M | 46.1M | 269.2M | 38.1M | 51M | 45.9M | 38.5M | 39.7M | 28.3M | |
294.7M | 332M | 414.3M | 656.4M | 511.2M | 227.7M | 237.8M | 232M | 207.3M | 200.8M | |
13.2M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 55K | 2.4M | 1.5M | |
455.1M | 542.4M | 589.8M | 960.4M | 692.1M | 350.3M | 326.8M | 297.5M | 295M | 252.9M | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 168M | 118M | |
83K | 82K | 79K | 78K | 75K | 285.2M | 285.1M | 285.2M | 113.4M | 113.4M | |
520.9M | 505.5M | 494.3M | 490.6M | 465.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-334.9M | -355.1M | -321.5M | -165.3M | -6.6M | -144.5M | -141.7M | -139.8M | -91.8M | -56.5M | |
-1.9M | -2.6M | 794K | -110K | 179K | 1.6M | -465K | -65K | -650K | 14K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.5M | 2.6M | |
184.1M | 147.9M | 173.6M | 325.2M | 458.9M | 142.2M | 143M | 145.3M | 192.3M | 177.5M | |
228.4M | 185.6M | 221.1M | 412.2M | 533.8M | 144.2M | 145.6M | 145.3M | 192.3M | 177.5M | |
44.3M | 37.7M | 47.5M | 87M | 74.9M | 1.9M | 2.6M | 0.0 | 0.0 | 0.0 | |
SUMMARY | ||||||||||
683.6M | 728M | 810.9M | 1.4B | 1.2B | 494.5M | 472.4M | 442.7M | 487.4M | 430.4M | |
0.0 | 0.0 | 0.0 | 2.6M | 29.3M | 19.4M | 3.3M | 2.8M | 0.0 | 0.0 | |
311.3M | 335.6M | 394.8M | 418.1M | 357.7M | 188.4M | 198M | 194.8M | 196.5M | 171M | |
260.1M | 294M | 357.9M | 387.9M | 313.7M | 101.5M | 133.4M | 152.1M | 191.6M | 155.2M | |
66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 | 66,926,984 |
BVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 22, 2026 | December 31, 2025 | 2025 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 27, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 |
Continue your BVS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.